PostEra enters a multi-year strategic partnership with Pfizer Inc. to advance machine learning for Drug Discovery
PostEra has formed a strategic partnership with Pfizer Inc. (NYSE: PFE), focusing on enhancing small molecule drug discovery through advanced machine learning technologies. This multi-year collaboration aims to develop a generative chemistry platform to optimize novel molecular structures.
PostEra will receive upfront payments and additional funding as the project progresses while retaining rights to all developed algorithms. Both companies will combine Pfizer's extensive data and PostEra's technological capabilities to address challenges in preclinical drug discovery.
- Partnership with Pfizer could accelerate drug discovery timelines.
- PostEra retains ownership of algorithms, ensuring long-term benefits.
- Collaboration leverages Pfizer's extensive data and expertise.
- None.
SAN FRANCISCO, Dec. 7, 2020 /PRNewswire/ -- PostEra, a biotechnology company specializing in machine learning solutions for preclinical drug discovery, today announced a strategic partnership with Pfizer Inc. (NYSE: PFE) with the goal of accelerating small molecule drug discovery by developing a platform technology based on generative chemistry.
PostEra's machine learning technology is intended to accelerate the drug discovery process by designing novel molecular structures with optimised potency and drug-like properties. PostEra's approaches take chemical synthesis into account, as well as incorporate design hypotheses of medicinal chemists.
Through the collaboration, the companies will leverage Pfizer's extensive data and expertise with PostEra's technology capabilities to advance the science of generative chemistry to produce state-of-the-art, scalable models that could potentially be deployed across in-house, preclinical drug discovery efforts.
PostEra will receive an upfront payment and is eligible to receive additional payments as the project progresses. PostEra will also retain ownership rights to all algorithms developed during the collaboration.
"PostEra is delighted to be working with Pfizer to solve some of the key pain points in preclinical drug discovery," said Aaron Morris, CEO of PostEra. "As a team we are proud to be entering this collaboration and will be leveraging PostEra's many advances in machine learning to help Pfizer accelerate progress toward novel therapeutics."
"We believe that our investments in machine learning technologies could potentially help us expedite preclinical drug discovery. PostEra's technology complements this effort, and we look forward to seeing the results of the collaboration," said Charlotte Allerton, Head of Medicine Design, Pfizer.
About PostEra
PostEra was founded in 2019 and its technology is built on pioneering academic research done at the University of Cambridge. The technology addresses some of the key challenges in drug discovery R&D by integrating molecular design with chemical synthesis. PostEra partners with drug hunters to help expedite their preclinical programs while also offering some of its synthesis technology via its Manifold web platform. PostEra also launched and now helps lead the world's largest open-science drug discovery effort; COVID Moonshot.
View original content:http://www.prnewswire.com/news-releases/postera-enters-a-multi-year-strategic-partnership-with-pfizer-inc-to-advance-machine-learning-for-drug-discovery-301187340.html
SOURCE PostEra
FAQ
What is the goal of PostEra's partnership with Pfizer?
When was the partnership between PostEra and Pfizer announced?
What will PostEra receive from Pfizer during the partnership?
What is the significance of PostEra's machine learning technology in drug discovery?
What rights does PostEra maintain during the collaboration with Pfizer?
